Literature DB >> 28078467

Clinical characteristics, risk factors and outcomes of asymptomatic rectal neuroendocrine tumors.

Sun-Hye Ko1, Myong Ki Baeg2, Seung Yeon Ko3, Hee Sun Jung4.   

Abstract

BACKGROUND: Rectal neuroendocrine tumors (NET) are often asymptomatic and frequently discovered during health examinations. However, data on the risk factors of asymptomatic rectal NETs are lacking. We investigated the risk factors, clinical characteristics and outcomes of asymptomatic rectal NETs discovered during health screening.
MATERIALS AND METHODS: Asymptomatic subjects who underwent colonoscopy during routine health screening at a tertiary hospital from March 2009 to July 2014 were reviewed. Subjects with histologically confirmed rectal NETs were compared with healthy controls from the same population. Risk factors for rectal NETs were analyzed by multivariable analysis. Clinical outcomes of the resected NETs were also analyzed.
RESULTS: A total of 21,706 Subjects underwent screening colonoscopy during the study period. 3417 were excluded from the study, and 180 rectal NET subjects were compared with 18,109 controls. Multivariable analysis showed that a previous history of malignancy (OR 2.960, 95% CI 1.673-5.237, p < 0.001), hypertriglyceridemia (OR 1.482, 95% CI 1.046-2.100, p = 0.027), higher fasting plasma glucose levels (OR 1.008, 95% CI 1.003-1.014, p = 0.001) and higher carcinoembryonic antigen levels (OR 1.019, 95% CI 1.003-1.035, p = 0.021) were significant risk factors while older age (OR 0.964, 95% CI 0.951-0.977, p < 0.001) was a preventive factor. One hundred and sixty nine subjects had endoscopic resection, five were treated by local surgery and six by radical surgery. Complete resection was achieved in 152 subjects. There were three cases of positive lymph nodes and one metastasis. Histology revealed four lymphatic, five vascular and two cases of perineural invasion. One hundred and fifty seven subjects were followed up for at least 1 year (median 38.6 months, 12-84 months). There were no recurrences during the follow-up period.
CONCLUSIONS: Younger age, previous history of malignancy, higher fasting plasma glucose levels and hypertriglyceridemia are significantly associated with rectal NET risk.

Entities:  

Keywords:  Health screening; Outcome; Rectal neuroendocrine tumor; Risk factor; Screening colonoscopy

Mesh:

Year:  2017        PMID: 28078467     DOI: 10.1007/s00464-016-5413-9

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  24 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

Review 2.  Rectal carcinoids are on the rise: early detection by screening endoscopy.

Authors:  H Scherübl
Journal:  Endoscopy       Date:  2009-02-12       Impact factor: 10.093

3.  PROX1 is involved in progression of rectal neuroendocrine tumors, NETs.

Authors:  Juha Jernman; Pauliina Kallio; Jaana Hagström; Matti J Välimäki; Hannu Haapasalo; Kari Alitalo; Johanna Arola; Caj Haglund
Journal:  Virchows Arch       Date:  2015-06-11       Impact factor: 4.064

Review 4.  Rectal carcinoids.

Authors:  Andrew Y Wang; Nuzhat A Ahmad
Journal:  Curr Opin Gastroenterol       Date:  2006-09       Impact factor: 3.287

5.  Characteristics and long-term prognosis of patients with rectal neuroendocrine tumors.

Authors:  Yihebali Chi; Feng Du; Hong Zhao; Jin-Wan Wang; Jian-Qiang Cai
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

6.  Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study.

Authors:  Manal M Hassan; Alexandria Phan; Donghui Li; Cecile G Dagohoy; Colleen Leary; James C Yao
Journal:  Int J Cancer       Date:  2008-08-15       Impact factor: 7.396

7.  Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study.

Authors:  Manal M Hassan; Alexandria Phan; Donghui Li; Cecile G Dagohoy; Colleen Leary; James C Yao
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-04       Impact factor: 4.254

Review 8.  The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction.

Authors:  G Rindi; G Petrone; F Inzani
Journal:  Endocr Pathol       Date:  2014-06       Impact factor: 3.943

9.  Standards of medical care in diabetes-2015 abridged for primary care providers.

Authors: 
Journal:  Clin Diabetes       Date:  2015-04

Review 10.  Screening for new primary cancers in cancer survivors compared to non-cancer controls: a systematic review and meta-analysis.

Authors:  Mark Corkum; Jill A Hayden; George Kephart; Robin Urquhart; Coralynne Schlievert; Geoffrey Porter
Journal:  J Cancer Surviv       Date:  2013-05-05       Impact factor: 4.442

View more
  3 in total

1.  Prognosis of rectal neuroendocrine tumors after endoscopic resection: a single-center retrospective study.

Authors:  Yue Zheng; Kehang Guo; Ruijie Zeng; Zhendao Chen; Wanwei Liu; Xiaoguang Zhang; Weimin Liang; Jianhua Liu; Hao Chen; Weihong Sha
Journal:  J Gastrointest Oncol       Date:  2021-12

Review 2.  Diagnosis and Management of Rectal Neuroendocrine Tumors (NETs).

Authors:  Francesco Maione; Alessia Chini; Marco Milone; Nicola Gennarelli; Michele Manigrasso; Rosa Maione; Gianluca Cassese; Gianluca Pagano; Francesca Paola Tropeano; Gaetano Luglio; Giovanni Domenico De Palma
Journal:  Diagnostics (Basel)       Date:  2021-04-25

Review 3.  Rectal neuroendocrine tumors: Current advances in management, treatment, and surveillance.

Authors:  Camilla Gallo; Roberta Elisa Rossi; Federica Cavalcoli; Federico Barbaro; Ivo Boškoski; Pietro Invernizzi; Sara Massironi
Journal:  World J Gastroenterol       Date:  2022-03-21       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.